

Working group to promote basic, clinical and economic research in the field of osteoarthritis

O. ETHGEN, **J.Y. REGINSTER**

Is the demographic transition impacting on the perception of degenerative musculoskeletal disorders.

Annals of Rheumatic Diseases, 2004; 63; 1-3

F. RICHY, O. BRUYERE, O. ETHGEN, V. RABENDA, G. BOUVENOT, M. AUDRAN, G. HERRERO-BEAUMONT, A. MOORE, R. ELIAKIM, M. HAIM, **J.Y. REGINSTER**

Time-dependant risk of gastrointestinal complications induced by NSAIDS use : a consensus statement using a meta-analytic approach.

Annals of Rheumatic Diseases, 2004; 63, 759-766

S. CHRISTGAU, Y. HENROTIN, L.B. TANKO, L.C. ROVATI, J. COLLETTE, O. BRUYERE, R. DEROISY, **J.Y. REGINSTER**

Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate.

Clinical and Experimental Rheumatology, 2004; 22, 36-42

O. ETHGEN, O. BRUYERE, F. RICHY, C. DARDENNE, **J.Y. REGINSTER**

Health-related quality of life in total hip and knee arthroplasties. A qualitative and systematic review of the literature.

Journal of Bone and Joint Surgery; 2004; 86-A, 963-974

E. ABADIE, D. ETHGEN, B. AVOUAC, G. BOUVENOT, J. BRANCO, O. BRUYERE, G. CALVO, J.P. DEVOGELAER, R.L. DREISER, G. HERRERO-BEAUMONT, A. KAHAN, G. KREUTZ, A. LASLOP, E.M. LEMMEL, G. NUKI, L. VAN DE PUTTE, L. VANHAELST, **J.Y. REGINSTER**, On behalf of the Group for the Respect of Excellence and Ethics in Science (GREES)

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.

Osteoarthritis and Cartilage; 2004; 12, 263-268

O. ETHGEN, P. VANPARIJS, S. DELHALLE, S. ROSANT, O. BRUYERE, **J.Y. REGINSTER**

Social support and health-related quality of life in hip and knee osteoarthritis.

Quality of Life Research, 2004; 13, 321-330

V. RABENDA, N. BURLET, O. ETHGEN, F. RAEMAN, J. BELAICHE, **J.Y. REGINSTER**

A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs.

Annals of Rheumatic Diseases, 2005; 64, 688-693

O. BRUYERE, F. RICHY, **J.Y. REGINSTER**

Three year joint space narrowing predicts long term incidence of knee surgery in patients with

osteoarthritis: an eight year prospective follow-up study.
Annals of Rheumatic Diseases, 2005; 64, 1727-1730

J.Y. REGINSTER, M.P. LECART, O. BRUYERE, N. BURLET

Glucosamine sulphate in osteoarthritis: from symptoms to structure modification.

Current Medical Chemistry – Anti-Inflammatory and Anti-Allergy Agents, 2005; 4, 217-220

R.D. ALTMAN, E. ABADIE, B. AVOUAC, G. BOUVENOT, J. BRANCO, O. BRUYERE, G. CALVO, J.P. DEVOGELAER, R.L. DREISER, G. HERRERO-BEAUMONT, A. KAHAN, G. KREUTZ, A. LASLOP, E.M. LEMMEL, C.J. MENKES, K. PAVELKA, L. VAN DE PUTTE, L. VANHAELST, **J.Y. REGINSTER**

Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.

Osteoarthritis and Cartilage, 2005; 13, 13-19

M. DEBERG, A. LABASSE, S. CHRISTGAU, P. CLOOS, D. BANG

HENRIKSEN, CHAPPELLE, B. ZEGELS, **J.Y. REGINSTER**, Y. HENROTIN

New serum biochemical markers (Coll 2-1 and Coll 2-1 NO₂) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid.

Osteoarthritis and Cartilage, 2005; 13, 258-265

C. SANCHEZ, M.A. DEBERG, N. PICCARDI, P. MSIKA, **J.Y.L. REGINSTER**, Y.E. HENROTIN

Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1 β and oncostatin M pre-treated non sclerotic osteoblasts.

Osteoarthritis and Cartilage, 2005; 13, 979-987

C. SANCHEZ, M.A. DEBERG, N. PICCARDI, P. MSIKA, **J.Y.L. REGINSTER**, Y.E. HENROTIN

Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes.

Osteoarthritis and Cartilage, 2005; 13, 988-997

M.A. DEBERG, A.H. LABASSE, J. COLLETTE, L. SEIDEL, **J.Y. REGINSTER**, H.E. HENROTIN

One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression.

Osteoarthritis and Cartilage, 2005; 13, 1059-1065

J-P. RAYNAULD, J. MARTEL-PELLETIER, M-J. BERTHIAUME, G. BEAUDOIN, D. CHOQUETTE, B. HARAoui, H. TANNENBAUM, J. M.MEYER, J.F. BEARY, G.A. CLINE, J-P.PELLETIER:

Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: Correlation with clinical symptoms and radiographic changes.

Arthritis Research Therapy 8: R21 {12 pages}, 2005 (full article online).

J-P. PELLETIER, C. BOILEAU, M. BOILY, J. BRUNET, F. MINEAU, C. GENG, P. REBOUL, S. LAUFER, D. LAJEUNESSE, J. MARTEL-PELLETIER:

The protective effect of Licofelone on experimental osteoarthritis is correlated with the downregulation of the expression and the synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K, and aggrecanases.

Arthritis Research Therapy 7: R1091-R1102, 2005.

C. BOILEAU, J.P. PELLETIER, G. TARDIF, H. FAHMI, S. LAUFER, , M. LAVIGNE, J. MARTEL-PELLETIER:

The regulation of human MMP-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signaling pathway.

Annals of Rheumatic Diseases 64: 891-898, 2005.

P. LAVIGNE, M. BENDERDOUR, D. LAJEUNESSE, P.REBOUL, Q.SHI, J.-P. PELLETIER, J. MARTEL-PELLETIER, J. FERNANDES

Subchondral and trabecular bone metabolism regulation in canine experimental knee osteoarthritis.

Osteoarthritis & Cartilage. 13: 310-317, 2005.

M-J. BERTHIAUME, J-P. RAYNAULD, J. MARTEL-PELLETIER, F. LABONTÉ, G.BEAUDOIN, D.A. BLOCH, D.CHOQUETTE, B. HARAOU, R.D. ALTMAN, M. HOCHBERG, J.M. MEYER, G.A. CLINE, J-P. PELLETIER

Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging.

Annals of Rheumatic Diseases 64: 556-563, 2005.

T. KOBAYASHI, K. NOTOYA, T. NAITO, S. UNNO, A. NAKAMURA, J. MARTEL-PELLETIER, J-P PELLETIER:

Pioglitazone, a PPAR γ agonist reduces the progression of experimental osteoarthritis in guinea pigs.

Arthritis & Rheumatism 52: 479-487, 2005.

C.A. MANACU, J. MARTEL-PELLETIER, M. ROY-BEAUDRY, J-P. PELLETIER, J.C. FERNANDES, F.S. SHIPKOLYE, D.R. MITROVIC, F. MOLDOVAN

Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and up-regulates collagenase production.

Arthritis Research Therapy 7: R324-R332, 2005.

C. BOILEAU, J. MARTEL-PELLETIER, J. BRUNET, G. TARDIF, D. SCHRIER, C. FLORY, A. EL-KATTAN, M. BOILY, J-P. PELLETIER

Oral treatment with PD-0200347, an $\alpha_2\delta$ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes.

Arthritis & Rheumatism 52: 488-500, 2005.

O. BRUYERE, J. COLLETTE, M. KOTHARI, S.ZAIM, D. WHITE, H.K. GENANT, C. PETERFY, N. BURLET, D. ETHGEN, T. MONTAGUE, C. DABROWSKI, **J.Y.**

REGINSTER

Osteoarthritis, magnetic resonance imaging and biochemical markers: a one-year prospective study.

Annals of Rheumatic Diseases, 2006; 65, 1050-1054

O. BRUYERE, **J.Y. REGINSTER**, G. GIACOVELLI, B. BARBETTA, L. ROVATI, K. PAVELKA

Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate

Arthritis and Rheumatism, 2006; 54, 2339-2341

V. RABENDA, N. BURLET, J. BELAICHE, F. RAEMAN, F. RICHY, **J.Y. REGINSTER**

Determinants of gastro-protective drugs co-prescription during treatment with non selective

NSAIDS: a prospective survey of 2197 patients recruited in primary care.
Osteoarthritis and Cartilage, 2006; 14, 625-630

L.C. ROVATI, K. PAVELKA, G. GIACOVELLI, **J.Y. REGINSTER**

Assessment of joint space narrowing with conventional standing antero-posterior radiographs: relief in mild-to-moderate pain is not a confounder in recent osteoarthritis structure-modifying drugs trials.
Osteoarthritis and Cartilage, 2006; 14, 14-18

Z. FAN, G. TARDIF, C. BOILEAU, J.P. BIDWELL, C. GENG, D. HUM, A. WATSON, J-P PELLETIER, M. LAVIGNE, J. MARTEL-PELLETIER

Identification in osteoarthritic chondrocytes of proteins binding to the novel regulatory site AGRE in the human MMP-13 proximal promoter.
Arthritis & Rheumatism. 54: 2471-2480, 2006.

C. BOILEAU, J. MARTEL-PELLETIER, J. BRUNET, D. SCHRIER, C. FLORY, M. BOILY, J-P. PELLETIER

PD-0200347, an $\alpha_2\delta$ ligand of voltage-gated calcium channel, inhibits in vivo the activation of the ERK1/2 pathway in osteoarthritic chondrocytes: A PKC α -dependent effect.
Annals of Rheumatic Diseases 65: 573-580, 2006.

F. MASSICOTTE, J.C. FERNANDES, J. MARTEL-PELLETIER, J-P. PELLETIER, D. LAJEUNESSE

Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts.
Bone 38: 333-341, 2006.

G. TARDIF, J-P PELLETIER, D. HUM, C. BOILEAU, N. DUVAL, J. MARTEL-PELLETIER

Differential regulation of the bone morphogenic protein antagonist chordin in human normal and osteoarthritic chondrocytes.
Annals of Rheumatic Diseases 65: 261-264, 2006.

J. MONFORT, G. TARDIF, P. REBOUL, F. MINEAU, P. ROUGHLEY, J-P. PELLETIER, J. MARTEL-PELLETIER

Degradation of small leucine-rich repeat proteoglycans by MMP-13: identification of a new biglycan cleavage site.
Arthritis Res. Ther. 8: R26 {9 pages}, 2006 (full article online).